ExeVir Bio

Startup

Our company specializes in creating innovative antibody therapies that aid patients in fighting off infectious diseases. We prioritize protecting individuals who are immunocompromised and therefore unable to benefit from current prevention and treatment approaches.

ExeVir is a clinical stage company, able to fast-track drug development using our modular VHH platform. Our first candidate drug progressed from research to the clinical in less than 1 year. The compound completed Phase 1a and Phase 1b studies and showed good pharmacodynamics and efficient GMP manufacturability.